Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 247


Mammary-specific ablation of Cyp24a1 inhibits development, reduces proliferation and increases sensitivity to vitamin D.

Sheng L, Turner AG, Barratt K, Kremer R, Morris HA, Callen DF, Anderson PH, Tarulli GA.

J Steroid Biochem Mol Biol. 2019 May;189:240-247. doi: 10.1016/j.jsbmb.2019.01.005. Epub 2019 Jan 14.


Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.

Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, Pop IL, Crompton BD, Lawlor ER, Tirode F, Mora J, Delattre O, Beckerle MC, Callen DF, Sharma S, Lessnick SL.

Mol Cancer Ther. 2018 Sep;17(9):1902-1916. doi: 10.1158/1535-7163.MCT-18-0373. Epub 2018 Jul 11.


Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.

Yap YS, Munusamy P, Lim C, Chan CHT, Prawira A, Loke SY, Lim SH, Ong KW, Yong WS, Ng SBH, Tan IBH, Callen DF, Lim JCT, Thike AA, Tan PH, Lee ASG.

Breast Cancer Res Treat. 2018 Oct;171(3):719-735. doi: 10.1007/s10549-018-4851-6. Epub 2018 Jun 21.


Vitamin D3 signaling and breast cancer: Insights from transgenic mouse models.

Sheng L, Callen DF, Turner AG.

J Steroid Biochem Mol Biol. 2018 Apr;178:348-353. doi: 10.1016/j.jsbmb.2018.02.006. Epub 2018 Feb 10. Review.


Naturally existing isoforms of miR-222 have distinct functions.

Yu F, Pillman KA, Neilsen CT, Toubia J, Lawrence DM, Tsykin A, Gantier MP, Callen DF, Goodall GJ, Bracken CP.

Nucleic Acids Res. 2017 Nov 2;45(19):11371-11385. doi: 10.1093/nar/gkx788.


Azobenzene-containing photoswitchable proteasome inhibitors with selective activity and cellular toxicity.

Blanco B, Palasis KA, Adwal A, Callen DF, Abell AD.

Bioorg Med Chem. 2017 Oct 1;25(19):5050-5054. doi: 10.1016/j.bmc.2017.06.011. Epub 2017 Jun 11.


Circulating Vitamin D and Overall Survival in Breast Cancer Patients: A Dose-Response Meta-Analysis of Cohort Studies.

Hu K, Callen DF, Li J, Zheng H.

Integr Cancer Ther. 2018 Jun;17(2):217-225. doi: 10.1177/1534735417712007. Epub 2017 Jun 7.


MiR-766 induces p53 accumulation and G2/M arrest by directly targeting MDM4.

Wang Q, Selth LA, Callen DF.

Oncotarget. 2017 May 2;8(18):29914-29924. doi: 10.18632/oncotarget.15530.


Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.

Shakya R, Tarulli GA, Sheng L, Lokman NA, Ricciardelli C, Pishas KI, Selinger CI, Kohonen-Corish MRJ, Cooper WA, Turner AG, Neilsen PM, Callen DF.

Oncogene. 2017 Aug;36(31):4469-4480. doi: 10.1038/onc.2017.66. Epub 2017 Apr 3.


New Peptidomimetic Boronates for Selective Inhibition of the Chymotrypsin-like Activity of the 26S Proteasome.

Zhang X, Adwal A, Turner AG, Callen DF, Abell AD.

ACS Med Chem Lett. 2016 Sep 13;7(12):1039-1043. eCollection 2016 Dec 8.


Cancer Detection in Human Tissue Samples Using a Fiber-Tip pH Probe.

Schartner EP, Henderson MR, Purdey M, Dhatrak D, Monro TM, Gill PG, Callen DF.

Cancer Res. 2016 Dec 1;76(23):6795-6801.


Identification of vitamin D3 target genes in human breast cancer tissue.

Sheng L, Anderson PH, Turner AG, Pishas KI, Dhatrak DJ, Gill PG, Morris HA, Callen DF.

J Steroid Biochem Mol Biol. 2016 Nov;164:90-97. doi: 10.1016/j.jsbmb.2015.10.012. Epub 2015 Oct 17.


Erratum: XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.

Pishas KI, Adwal A, Neuhaus SJ, Clayer MT, Farshid G, Staudacher AH, Callen DF.

Sci Rep. 2015 Aug 27;5:13328. doi: 10.1038/srep13328. No abstract available.


XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.

Pishas KI, Adwal A, Neuhaus SJ, Clayer MT, Farshid G, Staudacher AH, Callen DF.

Sci Rep. 2015 Jun 22;5:11465. doi: 10.1038/srep11465. Erratum in: Sci Rep. 2015;5:13328.


p53 Represses the Oncogenic Sno-MiR-28 Derived from a SnoRNA.

Yu F, Bracken CP, Pillman KA, Lawrence DM, Goodall GJ, Callen DF, Neilsen PM.

PLoS One. 2015 Jun 10;10(6):e0129190. doi: 10.1371/journal.pone.0129190. eCollection 2015.


Ankrd11 is a chromatin regulator involved in autism that is essential for neural development.

Gallagher D, Voronova A, Zander MA, Cancino GI, Bramall A, Krause MP, Abad C, Tekin M, Neilsen PM, Callen DF, Scherer SW, Keller GM, Kaplan DR, Walz K, Miller FD.

Dev Cell. 2015 Jan 12;32(1):31-42. doi: 10.1016/j.devcel.2014.11.031. Epub 2014 Dec 31.


Ankrd11 is a chromatin regulator involved in autism that is essential for neural development.

Voronova A, Gallagher D, Zander M, Cancino G, Bramall A, Krause MP, Abad C, Tekin M, Neilsen PM, Callen DF, Scherer SW, Keller GM, Kaplan DR, Walz K, Miller FD.

Springerplus. 2015 Jun 12;4(Suppl 1):L28. doi: 10.1186/2193-1801-4-S1-L28. eCollection 2015. No abstract available.


Characterization of ANKRD11 mutations in humans and mice related to KBG syndrome.

Walz K, Cohen D, Neilsen PM, Foster J 2nd, Brancati F, Demir K, Fisher R, Moffat M, Verbeek NE, Bjørgo K, Lo Castro A, Curatolo P, Novelli G, Abad C, Lei C, Zhang L, Diaz-Horta O, Young JI, Callen DF, Tekin M.

Hum Genet. 2015 Feb;134(2):181-90. doi: 10.1007/s00439-014-1509-2. Epub 2014 Nov 21.


The NF1 gene revisited - from bench to bedside.

Yap YS, McPherson JR, Ong CK, Rozen SG, Teh BT, Lee AS, Callen DF.

Oncotarget. 2014 Aug 15;5(15):5873-92. Review.


SCF-FBXO31 E3 ligase targets DNA replication factor Cdt1 for proteolysis in the G2 phase of cell cycle to prevent re-replication.

Johansson P, Jeffery J, Al-Ejeh F, Schulz RB, Callen DF, Kumar R, Khanna KK.

J Biol Chem. 2014 Jun 27;289(26):18514-25. doi: 10.1074/jbc.M114.559930. Epub 2014 May 14.


Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.

Pishas KI, Neuhaus SJ, Clayer MT, Schreiber AW, Lawrence DM, Perugini M, Whitfield RJ, Farshid G, Manavis J, Chryssidis S, Mayo BJ, Haycox RC, Ho K, Brown MP, D'Andrea RJ, Evdokiou A, Thomas DM, Desai J, Callen DF, Neilsen PM.

Cancer Res. 2014 Feb 1;74(3):921-31. doi: 10.1158/0008-5472.CAN-13-2424. Epub 2013 Dec 13.


TAp63 regulates oncogenic miR-155 to mediate migration and tumour growth.

Mattiske S, Ho K, Noll JE, Neilsen PM, Callen DF, Suetani RJ.

Oncotarget. 2013 Nov;4(11):1894-903.


A template-based approach to inhibitors of calpain 2, 20S proteasome, and HIV-1 protease.

Jones SA, Neilsen PM, Siew L, Callen DF, Goldfarb NE, Dunn BM, Abell AD.

ChemMedChem. 2013 Dec;8(12):1918-21. doi: 10.1002/cmdc.201300387. Epub 2013 Oct 15.


Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy.

Pishas KI, Neuhaus SJ, Clayer MT, Adwal A, Brown MP, Evdokiou A, Callen DF, Neilsen PM.

Oncol Rep. 2013 Jul;30(1):471-7. doi: 10.3892/or.2013.2454. Epub 2013 May 13.


Synthesis and extended activity of triazole-containing macrocyclic protease inhibitors.

Pehere AD, Pietsch M, Gütschow M, Neilsen PM, Pedersen DS, Nguyen S, Zvarec O, Sykes MJ, Callen DF, Abell AD.

Chemistry. 2013 Jun 10;19(24):7975-81. doi: 10.1002/chem.201204260. Epub 2013 Apr 18.


Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine.

Lim SP, Kumar R, Akkamsetty Y, Wang W, Ho K, Neilsen PM, Walther DJ, Suetani RJ, Prestidge C, Callen DF.

BMC Cancer. 2013 Mar 13;13:113. doi: 10.1186/1471-2407-13-113.


p53 continues to surprise: high levels of p53 can suppress apoptosis.

Callen DF.

Cell Cycle. 2013 Jan 15;12(2):203. doi: 10.4161/cc.23420. Epub 2012 Jan 15. No abstract available.


New 26S proteasome inhibitors with high selectivity for chymotrypsin-like activity and p53-dependent cytotoxicity.

Neilsen PM, Pehere AD, Pishas KI, Callen DF, Abell AD.

ACS Chem Biol. 2013 Feb 15;8(2):353-9. doi: 10.1021/cb300549d. Epub 2012 Nov 28.


Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.

Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB, Lim SP, Kumar R, Suetani RJ, Goodall GJ, Callen DF.

Oncogene. 2013 Jun 13;32(24):2992-3000. doi: 10.1038/onc.2012.305. Epub 2012 Jul 16.


A comparison of vitamin D activity in paired non-malignant and malignant human breast tissues.

Suetani RJ, Ho K, Jindal S, Manavis J, Neilsen PM, Pishas KI, Rippy E, Bochner M, Kollias J, Gill PG, Morris HA, Callen DF.

Mol Cell Endocrinol. 2012 Oct 15;362(1-2):202-10. doi: 10.1016/j.mce.2012.06.022. Epub 2012 Jun 29.


The oncogenic role of miR-155 in breast cancer.

Mattiske S, Suetani RJ, Neilsen PM, Callen DF.

Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1236-43. doi: 10.1158/1055-9965.EPI-12-0173. Epub 2012 Jun 26. Review.


Specific-site methylation of tumour suppressor ANKRD11 in breast cancer.

Lim SP, Wong NC, Suetani RJ, Ho K, Ng JL, Neilsen PM, Gill PG, Kumar R, Callen DF.

Eur J Cancer. 2012 Nov;48(17):3300-9. doi: 10.1016/j.ejca.2012.03.023. Epub 2012 Apr 24.


Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome.

Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, Lane DP, Callen DF.

Oncotarget. 2011 Dec;2(12):1203-17.


Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells.

Azad A, Jackson S, Cullinane C, Natoli A, Neilsen PM, Callen DF, Maira SM, Hackl W, McArthur GA, Solomon B.

Mol Cancer Res. 2011 Dec;9(12):1696-707. doi: 10.1158/1541-7786.MCR-11-0312. Epub 2011 Oct 18.


Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11.

Noll JE, Jeffery J, Al-Ejeh F, Kumar R, Khanna KK, Callen DF, Neilsen PM.

Oncogene. 2012 Jun 7;31(23):2836-48. doi: 10.1038/onc.2011.456. Epub 2011 Oct 10.


The application of delivery systems for DNA methyltransferase inhibitors.

Lim SP, Neilsen P, Kumar R, Abell A, Callen DF.

BioDrugs. 2011 Aug 1;25(4):227-42. doi: 10.2165/11592770-000000000-00000. Review.


Genome-wide mapping of ZNF652 promoter binding sites in breast cancer cells.

Kumar R, Selth LA, Schulz RB, Tay BS, Neilsen PM, Callen DF.

J Cell Biochem. 2011 Oct;112(10):2742-7. doi: 10.1002/jcb.23214.


Targeting the p53 Pathway in Ewing Sarcoma.

Neilsen PM, Pishas KI, Callen DF, Thomas DM.

Sarcoma. 2011;2011:746939. doi: 10.1155/2011/746939. Epub 2010 Dec 9.


Nutlin-3a is a potential therapeutic for ewing sarcoma.

Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, Callen DF, Neilsen PM.

Clin Cancer Res. 2011 Feb 1;17(3):494-504. doi: 10.1158/1078-0432.CCR-10-1587. Epub 2010 Nov 23.


Systematic characterisation of the rat and human CYP24A1 promoter.

Kumar R, Iachini DN, Neilsen PM, Kaplan J, Michalakas J, Anderson PH, May BK, Morris HA, Callen DF.

Mol Cell Endocrinol. 2010 Aug 30;325(1-2):46-53. doi: 10.1016/j.mce.2010.04.023. Epub 2010 May 5.


Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma.

Lamprecht B, Walter K, Kreher S, Kumar R, Hummel M, Lenze D, Köchert K, Bouhlel MA, Richter J, Soler E, Stadhouders R, Jöhrens K, Wurster KD, Callen DF, Harte MF, Giefing M, Barlow R, Stein H, Anagnostopoulos I, Janz M, Cockerill PN, Siebert R, Dörken B, Bonifer C, Mathas S.

Nat Med. 2010 May;16(5):571-9, 1p following 579. doi: 10.1038/nm.2129. Epub 2010 May 2.


Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome.

Callen DF, Ricciardelli C, Butler M, Stapleton A, Stahl J, Kench JG, Horsfall DJ, Tilley WD, Schulz R, Nesland JM, Neilsen PM, Kumar R, Holm R.

Oncol Rep. 2010 Apr;23(4):1045-52.


CBFA2T3-ZNF651, like CBFA2T3-ZNF652, functions as a transcriptional corepressor complex.

Kumar R, Cheney KM, Neilsen PM, Schulz RB, Callen DF.

FEBS Lett. 2010 Mar 5;584(5):859-64. doi: 10.1016/j.febslet.2010.01.047. Epub 2010 Jan 30.


Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance.

Tischfield MA, Baris HN, Wu C, Rudolph G, Van Maldergem L, He W, Chan WM, Andrews C, Demer JL, Robertson RL, Mackey DA, Ruddle JB, Bird TD, Gottlob I, Pieh C, Traboulsi EI, Pomeroy SL, Hunter DG, Soul JS, Newlin A, Sabol LJ, Doherty EJ, de Uzcátegui CE, de Uzcátegui N, Collins ML, Sener EC, Wabbels B, Hellebrand H, Meitinger T, de Berardinis T, Magli A, Schiavi C, Pastore-Trossello M, Koc F, Wong AM, Levin AV, Geraghty MT, Descartes M, Flaherty M, Jamieson RV, Møller HU, Meuthen I, Callen DF, Kerwin J, Lindsay S, Meindl A, Gupta ML Jr, Pellman D, Engle EC.

Cell. 2010 Jan 8;140(1):74-87. doi: 10.1016/j.cell.2009.12.011.


Mechanistic insight into cell growth, internalization, and cytotoxicity of PAMAM dendrimers.

Parimi S, Barnes TJ, Callen DF, Prestidge CA.

Biomacromolecules. 2010 Feb 8;11(2):382-9. doi: 10.1021/bm9010134.


Identification of ANKRD11 as a p53 coactivator.

Neilsen PM, Cheney KM, Li CW, Chen JD, Cawrse JE, Schulz RB, Powell JA, Kumar R, Callen DF.

J Cell Sci. 2008 Nov 1;121(Pt 21):3541-52. doi: 10.1242/jcs.026351. Epub 2008 Oct 7.


CBFA2T3-ZNF652 corepressor complex regulates transcription of the E-box gene HEB.

Kumar R, Cheney KM, McKirdy R, Neilsen PM, Schulz RB, Lee J, Cohen J, Booker GW, Callen DF.

J Biol Chem. 2008 Jul 4;283(27):19026-38. doi: 10.1074/jbc.M709136200. Epub 2008 May 2.


Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis.

Holm R, Knopp S, Kumar R, Lee J, Nesland JM, Tropè C, Callen DF.

J Clin Pathol. 2008 Jan;61(1):59-63. Epub 2007 Apr 27.


ZNF652, a novel zinc finger protein, interacts with the putative breast tumor suppressor CBFA2T3 to repress transcription.

Kumar R, Manning J, Spendlove HE, Kremmidiotis G, McKirdy R, Lee J, Millband DN, Cheney KM, Stampfer MR, Dwivedi PP, Morris HA, Callen DF.

Mol Cancer Res. 2006 Sep;4(9):655-65.


FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex.

Kumar R, Neilsen PM, Crawford J, McKirdy R, Lee J, Powell JA, Saif Z, Martin JM, Lombaerts M, Cornelisse CJ, Cleton-Jansen AM, Callen DF.

Cancer Res. 2005 Dec 15;65(24):11304-13.

Supplemental Content

Loading ...
Support Center